Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
María-Carlota LondoñoMar Riveiro-BarcielaAdriana AhumadaRaquel Muñoz-GómezMercé RogetMaría J Devesa-MedinaMiguel Ángel SerraCarmen A NavascuésCarme BaliellasTeresa Aldamiz-EchevarríaMaría L GutiérrezBenjamín Polo-LorduyIsabel CarmonaSalvador BenllochLucía BonetJavier García-SamaniegoMiguel Jiménez-PérezSenador Morán-SánchezÁngeles CastroManuel DelgadoFrancisco Gea-RodríguezIgnacio Martín-GranizoMaría Luisa MontesLuis Enrique MoranoManuel A CastañoIgnacio de Los SantosMontserrat LagunoJuan-Emilio Losa-GarcíaMarta Montero-AlonsoAntonio RiveroCristina de ÁlvaroAmanda ManzanaresJosep MallolasGuillermina BarrilEmilio González-ParraLuisa García-BueyPublished in: PloS one (2019)
These results have shown that 3D/2D regimens are effective and tolerable in patients with advanced CKD including those in dialysis with GT 1 or 4 chronic HCV mono-infection and HIV/HCV coinfection in a real-life cohort. The overall SVR12 rates were 92.6% (ITT) and 99.2% (mITT) without clinically relevant changes in eGFR until 12 weeks post-treatment. These results are consistent with those reported in clinical trials.
Keyphrases
- chronic kidney disease
- hepatitis c virus
- end stage renal disease
- human immunodeficiency virus
- antiretroviral therapy
- clinical trial
- clinical practice
- hiv positive
- hiv testing
- hiv infected
- small cell lung cancer
- randomized controlled trial
- hiv aids
- systematic review
- open label
- epidermal growth factor receptor
- men who have sex with men
- tyrosine kinase
- gestational age